Azria D, Hennequin C, Giraud P
IRCM, Institut de recherche en cancérologie de Montpellier (U1194), 208, avenue des Apothicaires, 34298 Montpellier cedex 5, France; Inserm, U1194, 208, avenue des Apothicaires, 34298 Montpellier cedex 5, France; Université de Montpellier, centre de recherche U1194, 208, avenue des Apothicaires, 34298 Montpellier cedex 05, France; Fédération universitaire d'oncologie radiothérapie, ICM, institut régional du cancer de Montpellier, rue Croix-Verte, 34298 Montpellier cedex 05, France.
Service de cancérologie-radiothérapie, AP-HP, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris, France.
Cancer Radiother. 2020 Jun;24(3):182-187. doi: 10.1016/j.canrad.2020.04.001. Epub 2020 Apr 10.
Overall treatment time is an important factor of local recurrence and indirectly of distant evolution, namely in case of protracted treatments. The current pandemic impacts on the duration of radiotherapy if patients under treatments and synchronously suffering from COVID-19. The models used to compensate the total dose in case of temporary treatment interruption are well known but it is of importance in that pandemic context to update and homogenize clinical practice in order to improve local control without increasing normal tissue complications.
总体治疗时间是局部复发的一个重要因素，对于远处进展也有间接影响，即在治疗时间延长的情况下。如果正在接受治疗的患者同时感染了新冠病毒，当前的疫情会影响放疗疗程的时长。用于在治疗暂时中断时补偿总剂量的模型是众所周知的，但在这种疫情背景下，更新并统一临床实践以在不增加正常组织并发症的情况下提高局部控制率非常重要。
